Table 94Subgroup and sensitivity analyses: chlorpromazine vs. clozapine – Total Score (BPRS)

Total Symptoms (BPRS)StudiesParticipantsEffect EstimateI2Favors
OVERALL POOLED RESULTS65358.40 (5.92, 10.88)20%clozapine
Race
Asian2804.73 (−0.39,9.85)0%ND
Mixed44559.57 (7.36,11.8)0%clozapine
First time vs. other
Previous episodes44749.63 (7.40,11.86)0%clozapine
Mixed first and previous episodes2614.77 (−0.17,9.71)0%ND
Treatment resistance
Treatment resistant230810.22 (7.12,13.33)10%clozapine
Mixed42276.96 (3.94,9.97)0%clozapine
Duration of followup
>6weeks31916.70 (3.55, 9.84)0%clozapine
≤6weeks330410.32 (7.66, 12.98)0%clozapine
Dosage of FGA (chlorpromazine)
Up to 1800mg/d44749.63 (7.40,11.9)0%clozapine
Maximum 100 and 600mg/d2614.77 (−0.17,9.71)0%ND
Source of funding
Industry funding228311.1 (8.13,14.0)0%clozapine
No industry funding reported42526.72 (3.89, 9.54)0%clozapine
Risk of bias
Unclear43638.23 (3.82, 12.6)45%clozapine
High21727.59 (4.20, 11.0)0%clozapine
Imputations
Data imputed32066.77 (2.39, 11.15)20%clozapine
No data imputed33299.70 (7.03, 12.37)5%clozapine

Significant results are in bold. BPRS = Brief Psychiatric Rating Scale; d = day; FGA = first generation antipsychotic; I2 = I–squared; mg = milligrams; ND = no difference

From: Appendix M, Subgroup and Sensitivity Analyses

Cover of First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet].
Comparative Effectiveness Reviews, No. 63.
Abou-Setta AM, Mousavi SS, Spooner C, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.